Disease · MONDO_0006909

pituitary dwarfism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pituitary dwarfism. Diseases, record MONDO_0006909. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006909

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pituitary dwarfism; Open Targets
Open Targets ID: MONDO_0006909; Open Targets
Other names: Dwarfism, Pituitary, Dwarfism: [pituitary] or [hypophyseal (& Lorain-Levi)], Lorain - Levi dwarfism, hypopituitary dwarfism; Open Targets
MeSH: D004393; MeSH
Highest stage of its drugs: Approval, for 4 of its 8 drugs, from DailyMed, EMA Human Drugs and FDA; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SOMATROPIN	CHEMBL1201621	Protein	Approval	DailyMed and EMA Human Drugs	42	31	31	Drugs and targets
SOMATROGON	CHEMBL4297830	Protein	Approval	FDA	3	2	2	Drugs and targets
LONAPEGSOMATROPIN	CHEMBL4298185	Protein	Approval	FDA	3	1	1	Drugs and targets
ARGININE HYDROCHLORIDE	CHEMBL1200381	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ALBUSOMATROPIN	CHEMBL4298125		Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
SOMAVARATAN	CHEMBL3707323	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MECASERMIN RINFABATE	CHEMBL1201717	Protein	Unknown	EMA Human Drugs	1	0	0	Drugs and targets
REDALSOMATROPIN ALFA	CHEMBL6068166	Protein	Unknown	INN	1	0	0	Drugs and targets

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GHR	Growth hormone receptor	3	Growth hormone receptor agonist	Approval	https://conductscience.org/library/genes/2690	Drugs and targets
IGF1R	Insulin-like growth factor 1 receptor	1	Insulin-like growth factor I receptor agonist	Unknown	https://conductscience.org/library/genes/3480	Drugs and targets

Trials36

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00256126	Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®	Phase 4	318	2018-03-20	Growth Hormone Deficiency, Turner Syndrome	SOMATROPIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04615273	A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency	Phase 3	264	2025-01-15	Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency	LONAPEGSOMATROPIN, SOMATROPIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT03831880	Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD	Phase 3	87	2021-10-14	Growth Hormone Deficiency	SOMATROGON	Open Targets' reading of its record	ClinicalTrials.gov
NCT02311894	A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency	Phase 4	82	2018-11-15	Growth Hormone Deficiency	SOMATROPIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT03874013	Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency	Phase 3	44	2021-08-12	Growth Hormone Deficiency	SOMATROGON, SOMATROPIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00191165	Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency	Phase 3	27	2009-06-08	Growth Hormone Deficiency	SOMATROPIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00957671	Anterior Pituitary Hormone Replacement in Traumatic Brain Injury	Phase 4	15	2018-05-15	Growth Hormone Deficiency, Traumatic Brain Injury	SOMATROPIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02410343	Study of TV-1106 in Growth Hormone-Deficient Adults	Phase 3	14	2018-06-11	Growth Hormone Deficiency	ALBUSOMATROPIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00555009	Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury	Phase 4	10	2010-06-02	Brain Injuries, Growth Hormone Deficiency	SOMATROPIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00630487	Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency	Phase 3	9	2011-01-27	Growth Hormone Deficiency	SOMATROPIN	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 36

See all 36 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Turner Syndrome (TS) vs Growth Hormone Deficiency (GHD): serious adverse events	0 of 149	1 of 169	318	NCT00256126	Trial comparisons
Genotropin vs Somatrogon: deaths from any cause	0 of 86	0 of 87	173	NCT03831880	Trial comparisons
Genotropin vs Somatrogon: Number of Participants With Discontinuation Due to Adverse Events (AEs)	0 of 86	1 of 87	173	NCT03831880	Trial comparisons
Genotropin vs Somatrogon: serious adverse events	0 of 86	0 of 87	173	NCT03831880	Trial comparisons
MOD-4023 Treatment Arm vs Genotropin Treatment Arm: deaths from any cause	0 of 22	0 of 22	44	NCT03874013	Trial comparisons
MOD-4023 Treatment Arm vs Genotropin Treatment Arm: serious adverse events	2 of 22	2 of 22	44	NCT03874013	Trial comparisons
Genotropin vs Placebo: serious adverse events	0 of 4	0 of 6	10	NCT00555009	Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33879807	RESULT	1	PubMed
28566441	RESULT	2	PubMed
23567489	RESULT	1	PubMed
41183961	DERIVED	1	PubMed
40047762	DERIVED	1	PubMed
36034802	DERIVED	1	PubMed
36034448	DERIVED	1	PubMed
35945517	DERIVED	1	PubMed
34899612	DERIVED	1	PubMed
34045667	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006909

GET https://conductscience.org/api/diseases/v1/MONDO_0006909/trials?page=2

API reference For AI assistants